# Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

> **NCT00450008** · PHASE2 · TERMINATED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 9 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** GM-CSF
- **DRUG:** thalidomide
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00450008
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2008-08
- **Final completion:** 2008-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** PI decision
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450008, "Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00450008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*